Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Catalent (DE:0C8)
FRANKFURT:0C8
Catalent (0C8) Stock Price & Analysis
1 Followers
0C8 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€29.20 - €57.00
Previous Close€52.29
Volume0.00
Average Volume (3M)149.00
Market Cap
€9.47B
Enterprise Value€13.93B
Total Cash (Recent Filing)$229.00M
Total Debt (Recent Filing)$5.00B
Price to Earnings (P/E)N/A
Beta0.34
Next Earnings
Apr 30, 2024EPS Estimate
€0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding180,737,675
10 Day Avg. Volume4
30 Day Avg. Volume149
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)23.79
Price to Sales (P/S)2.21
Price to Cash Flow (P/CF)22.60
P/FCF Ratio27.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.40
Enterprise Value/Gross Profit13.39
Enterprise Value/Ebitda-18.72
Forecast
1Y Price Target
€56.74Price Target Upside9.63% Upside
Rating ConsensusHold
Number of Analyst Covering7
Catalent News
Bulls Say, Bears Say
Bulls Say
AcquisitionCatalent maintains an Outperform rating and a $63.50 price target based on the proposed acquisition by Novo Holdings.
Operational CapacityCTLT's syringe capacity is approximately 600 million per year, with fill/finish pricing on the rise, indicating strong operational capabilities and potential for increased profitability.
Strategic PartnershipCatalent's long-term contract with Sarepta to manufacture ELEVIDYS is confirmed to continue until December 31, 2028, ensuring stable revenue streams.
Bears Say
Company OperationsCTLT's Belgium and Bloomington facilities have been subject to quality and production issues, impacting the company's reputation and operations.
Financial PerformanceCTLT's F2Q24 results were underwhelming, with the top-line beat offset by lower margins and quality issues lingering.
Regulatory ChallengesRegulatory review could challenge the vertical integration, potentially affecting CTLT's fill/finish customer base.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.12% Other Institutional Investors
98.88% Public Companies and
Individual Investors
0C8 FAQ
What was Catalent’s price range in the past 12 months?
Catalent lowest stock price was €29.20 and its highest was €57.00 in the past 12 months.
What is Catalent’s market cap?
Currently, no data Available
When is Catalent’s upcoming earnings report date?
Catalent’s upcoming earnings report date is Apr 30, 2024 which is in 3 days.
How were Catalent’s earnings last quarter?
Catalent released its earnings results on Feb 09, 2024. The company reported -€0.224 earnings per share for the quarter, missing the consensus estimate of -€0.02 by -€0.205.
Is Catalent overvalued?
According to Wall Street analysts Catalent’s price is currently Undervalued.
Does Catalent pay dividends?
Catalent does not currently pay dividends.
What is Catalent’s EPS estimate?
Catalent’s EPS estimate is €0.2.
How many shares outstanding does Catalent have?
Currently, no data Available
What happened to Catalent’s price movement after its last earnings report?
Catalent reported an EPS of -€0.224 in its last earnings report, missing expectations of -€0.02. Following the earnings report the stock price went down -0.943%.
Which hedge fund is a major shareholder of Catalent?
Among the largest hedge funds holding Catalent’s share is Elliott Investment Management LP. It holds Catalent’s shares valued at 180M.
---
Catalent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€56.74 (9.63% Upside)
€56.74 (9.63% Upside)
Blogger Sentiment
Neutral
DE:0C8 Sentiment 72%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.72%
12-Months-Change
Fundamentals
Return on Equity
-29.72%
Trailing 12-Months
Asset Growth
-10.40%
Trailing 12-Months
Company Description
Catalent
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. It operates through the following segments: Softgel Technologies; Biologics and Specialty Drug Delivery; Oral Drug Delivery; and Clinical Supply Services. The Softgel Technologies segment formulate, develop, and manufacture services for soft capsules. The Biologics and Specialty Drug Delivery segment develops and manufacture services for blow-fill-seal unit doses, prefilled syringes, vials, and cartridges; analytical development and testing services for large molecules; inhaled products for delivery via metered dose inhalers, dry powder inhalers, and intra-nasal sprays. The Oral Drug Delivery segment focuses in the formulation development and manufacturing technologies, and related solutions including: clinical development and commercial manufacturing of a range of oral dose forms, including proprietary fast-dissolve Zydis tablets and both conventional immediate and controlled release tablets, capsules, and sachet products. The Clinical Supply Services segment includes packaging, labeling, storage, distribution, and inventory management for drugs and biologics in clinical trials. The company was founded in April 2007 and is headquartered in Somerset, NJ.
---
0C8 Company Deck
---
0C8 Earnings Call
Q1 2023
0:00 / 0:00
---
0C8 Stock 12 Months Forecast
Average Price Target
€56.74
▲(9.63% Upside)
Technical Analysis
Best Analysts Covering 0C8
1 Year
1 Year Success Rate
4/11 ratings generated profit
1 Year Average Return
-12.12%
reiterated a buy rating 6 months ago
Copying Tejas Savant's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -12.12% per trade.
---